Blueprint Medicines Corp (BPMC)

100.85
-3.44(-3.30%)
After Hours
100.85
0.00(0.00%)
- Real-time Data
  • Volume:
    265,861
  • Bid/Ask:
    80.00/122.22
  • Day's Range:
    99.45 - 103.52

BPMC Overview

Prev. Close
104.29
Day's Range
99.45-103.52
Revenue
107.18M
Open
102.74
52 wk Range
79.07-125.61
EPS
-7.1
Volume
265,861
Market Cap
5.93B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
362,818
P/E Ratio
-
Beta
0.67
1-Year Change
-4.24%
Shares Outstanding
58,838,034
Next Earnings Date
Mar 11, 2022
What is your sentiment on Blueprint Medicines Corp?
or
Market is currently closed. Voting is open during market hours.

Blueprint Medicines Corp Company Profile

Employees
476

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Blueprint Medicines Corporation has a strategic research collaboration with The University of Texas MD Anderson Cancer Center for accelerating development of BLU-222, an investigational precision therapy that targets cyclin-dependent kinase 2. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellBuy
Technical IndicatorsStrong BuySellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • There we go. Not big profit but a profit in a red day for the industry.
    0
    • Anyone loading for tomorrow? I am.
      0
      • bought on the dip, fda going to spike the price
        0
        • where is the spike ?
          0
      • https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00247-3/fulltext
        0
        • PDUFA date coming up
          0
          • the average target price is 93.5 and the high target price is 122 why is nobody buying?
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.